Skin Stripping Bioequivalence Endorsement Expected In FDA Guidance
This article was originally published in The Rose Sheet
Executive Summary
FDA is expected to advocate dermatopharmacokinetics (skin stripping) as a method to determine bioequivalence (BE) of dermatologic drugs in an upcoming guidance document, FDA Office of Pharmaceutical Sciences Senior Research Scientist Vinod Shah, PhD, said.
You may also be interested in...
In Vitro Release Studies Would Serve As DPK Adjunct Under FDA Proposal
In vitro drug release studies would be required as an adjunct to dermatopharmacokinetics (skin stripping) for establishing the bioequivalence of topical drug products under proposed changes to an FDA draft guidance.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program